연구동향 분석
박사

The Association between High Dose Radioactive Iodine Therapy and Telomeric and Chromosomal Damage in Thyroid Cancer Patients = 갑상선암 환자에서 고용량 방사성 요오드 치료와 텔로미어 및 염색체 손상 간의 연관성

최훈성 2016년

논문상세정보
인용/피인용
' The Association between High Dose Radioactive Iodine Therapy and Telomeric and Chromosomal Damage in Thyroid Cancer Patients = 갑상선암 환자에서 고용량 방사성 요오드 치료와 텔로미어 및 염색체 손상 간의 연관성' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • chromosomal fragility
  • cumulative dose
  • htert
  • radioactive iodine
  • second malignancy
  • telomere
  • thyroid cancer
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
4,007 0

0.0%

' The Association between High Dose Radioactive Iodine Therapy and Telomeric and Chromosomal Damage in Thyroid Cancer Patients = 갑상선암 환자에서 고용량 방사성 요오드 치료와 텔로미어 및 염색체 손상 간의 연관성' 의 참고문헌

  • d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Zglinicki Von T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003 Nov 13;426(6963):194–8.
  • Wang L, Soria J-C, Kemp BL, Liu DD, Mao L, Khuri FR. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res. 2002 Sep;8(9):2883–9.
  • Unryn BM, Hao D, Gl ck S, Riabowol KT. Acceleration of Telomere Loss by Chemotherapy Is Greater in Older Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. American Association for Cancer Research; 2006 Nov 1;12(21):6345–50.
  • Sundaram PS, Padma S, Sudha S, Sasikala K. Transient cytotoxicity of I beta radiation in hyperthyroid patients treated with radioactive iodine. Indian J Med Res. 2011 Apr;133:401–6.
  • Slijepcevic P, Bryant PE. Chromosome healing, telomere capture and mechanisms of radiation-induced chromosome breakage. Int J Radiat Biol. 1998 Jan;73(1):1–13.
  • Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V, et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene. Nature Publishing Group; 2003 Jan 9;22(1):131–46.
  • Seo GH, Cho YY, Chung JH, Kim SW. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea. Thyroid. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA; 2015 Aug;25(8):927–34.
  • Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer. Journal of Clinical Endocrinology & Metabolism. 2004 Aug;89(8):3668–76.
  • Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009 May;19(5):451–7.
  • Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA; 2010 Nov;20(11):1235–45.
  • Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015 Apr;100(4):1529–36.
  • Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003 Nov 3;89(9):1638–44.
  • Rosendorff J, Bernstein R. Fanconi's anemia--chromosome breakage studies in homozygotes and heterozygotes. Cancer Genet Cytogenet. 1988 Jul 15;33(2):175– 83.
  • Raynaud CM, Sabatier L, Philipot O, Olaussen KA, Soria J-C. Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. Critical Reviews in Oncology/Hematology. 2008 May;66(2):99–117.
  • Ram rez MJ, Puerto S, Galofr P, Parry EM, Parry JM, Creus A, et al. Multicolour FISH detection of radioactive iodine-induced 17cen-p53 chromosomal breakage in buccal cells from therapeutically exposed patients. Carcinogenesis. 2000 Aug;21(8):1581–6.
  • Qin Y, Tang B, Hu C-J, Xiao Y-F, Xie R, Yong X, et al. An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer. Oncotarget. Impact Journals; 2015 Oct 20;5(0).
  • Park Y-J, Kim EK, Bae JY, Moon S, Kim J. Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1. Cancer Lett. 2015 Oct 28.
  • Murnane JP. Telomere dysfunction and chromosome instability. Mutat Res [Internet]. Elsevier B.V; 2012 Feb 1;730(1-2):28–36. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0027510711000911
  • Melin BS, Nordfj ll K, Andersson U, Roos G. hTERT Cancer Risk Genotypes Are Associated With Telomere Length. Genet Epidemiol. 2012 Apr 26;36(4):368–72.
  • Marti JL, Jain KS, Morris LGT. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid. 2015 Jun;25(6):681–7.
  • Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, Dunning AM, et al. Shortened Telomere Length Is Associated with Increased Risk of Cancer: A Meta-Analysis. Toland AE, editor. PLoS ONE. 2011 Jun 10;6(6):e20466.
  • Liou M-J, Chan E-C, Lin J-D, Liu F-H, Chao T-C. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Cancer Lett. 2003 Mar 10;191(2):223–7.
  • Li P, Hou M, Lou F, Bj rkholm M, Xu D. Telomere dysfunction induced by chemotherapeutic agents and radiation in normal human cells. International Journal of Biochemistry and Cell Biology [Internet]. Elsevier Ltd; 2012 Sep 1;44(9):1531– 40. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1357272512002191
  • Lee JJ, Nam CE, Cho SH, Park KS, Chung IJ, Kim HJ. Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy. Ann Hematol. Springer-Verlag; 2003;82(8):492–5.
  • Kirkpatrick KL, Clark G, Ghilchick M, Newbold RF, Mokbel K. hTERT mRNA expression correlates with telomerase activity in human breast cancer. European Journal of Surgical Oncology (EJSO). 2003 May;29(4):321–6.
  • Kim C, Bi X, Pan D, Chen Y, Carling T, Ma S, et al. The Risk of Second Cancers After Diagnosis of Primary Thyroid Cancer Is Elevated in Thyroid Microcarcinomas. Thyroid. 2013 May;23(5):575–82.
  • Khang AR, Cho SW, Choi HS, ahn HY, Yoo WS, kim KW, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131) I dose over 37 GBq. Clinical Endocrinology. 2014 Aug 13.
  • Julin B, Shui I, Heaphy CM, Joshu CE, Meeker AK, Giovannucci E, et al. Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. Br J Cancer. 2015 Feb 17;112(4):769–76.
  • Iyer NG, Morris LGT, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. Wiley Subscription Services, Inc., A Wiley Company; 2011 Oct 1;117(19):4439–46.
  • Ilyenko I, Lyaskivska O, Bazyka D. Analysis of relative telomere length and apoptosis in humans exposed to ionising radiation. Exp Oncol. 2011 Dec;33(4):235–8.
  • Haugen BR MD, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 Oct 14;:thy.2015.0020–411.
  • Hartmann U, Brummendorf TH, Balabanov S. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. …. 2005.
  • Chung J-K. Sodium Iodide Symporter: Its Role in Nuclear Medicine. J Nucl Med. Society of Nuclear Medicine; 2002 Sep 1;43(9):1188–200.
  • Choi H, Lim JA, Ahn HY, Cho SW, Lee KE, Kim KW, et al. Secular trends in the prognostic factors for papillary thyroid cancer. Eur J Endocrinol. 2014 Oct 8;171(5):667–75.
  • Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Research. Oxford University Press; 2009 Feb;37(3):e21–1.
  • Cairney CJ, Keith WN. Telomerase redefined: Integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie. 2008 Jan;90(1):13–23.
  • Bosch PC, Bogliolo M, Surrall s J. Activation of the Fanconi anemia/BRCA pathway at low doses of ionization radiation. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 2015 Nov;793:9–13.
  • Barrios L, Mir R, Caball n MR, Fuster C, Guedea F, Subias A, et al. Cytogenetic effects of radiotherapy breakpoint distribution in induced chromosome aberrations. Cancer Genet Cytogenet. 1989 Aug;41(1):61–70.
  • Ammenheuser MM, Au WW, Whorton EB, Belli JA, Ward JB. Comparison of Hprt variant frequencies and chromosome aberration frequencies in lymphocytes from radiotherapy and chemotherapy patients: A Prospective Study. Environmental and Molecular Mutagenesis. Wiley Subscription Services, Inc., A Wiley Company; 1991 Jan 1;18(2):126–35.
  • American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009. pp. 1167–214.
  • Ahola K, Sir n I, Kivim ki M, Ripatti S, Aromaa A, L nnqvist J, et al. Workrelated exhaustion and telomere length: a population-based study. Ahola K, Sir n I, Kivim ki M, Ripatti S, Aromaa A, L nnqvist J, et al., editors. PLoS ONE. 2012 Jul 11;7(7):e40186.